{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T06:07:37Z","timestamp":1775110057741,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ningbo Public Welfare Technology Research Project","award":["2025S170"],"award-info":[{"award-number":["2025S170"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04603-w","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:53:40Z","timestamp":1775105620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interpretable machine learning model for immune-related hyperthyroidism prediction in patients receiving immune checkpoint inhibitors: A retrospective study"],"prefix":"10.1007","volume":"91","author":[{"given":"Tongtong","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingqing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"4603_CR1","doi-asserted-by":"publisher","first-page":"1432813","DOI":"10.3389\/fimmu.2024.1432813","volume":"15","author":"K Chen","year":"2024","unstructured":"K. Chen, X. Wang, R. Yue et al., Efficacy and safety of immune checkpoint inhibitors as neoadjuvant therapy in perioperative patients with non-small cell lung cancer: A network meta-analysis and systematic review based on randomized controlled trials. Front. Immunol. 15, 1432813 (2024). https:\/\/doi.org\/10.3389\/fimmu.2024.1432813","journal-title":"Front. Immunol."},{"key":"4603_CR2","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"C. Robert, A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun. 11, 3801 (2020). https:\/\/doi.org\/10.1038\/s41467-020-17670-y","journal-title":"Nat. Commun."},{"key":"4603_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"DM Pardoll, The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 12, 252\u2013264 (2012). https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat. Rev. Cancer"},{"key":"4603_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejca.2020.11.010","volume":"144","author":"C Robert","year":"2021","unstructured":"C. Robert, W.-J. Hwu, O. Hamid et al., Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. Eur. J. Cancer. 144, 182\u2013191 (2021). https:\/\/doi.org\/10.1016\/j.ejca.2020.11.010","journal-title":"Eur. J. Cancer"},{"key":"4603_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"M.A. Postow, R. Sidlow, M.D. Hellmann, Immune-related adverse events associated with immune checkpoint blockade. N Engl. J. Med. 378, 158\u2013168 (2018). https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl. J. Med."},{"key":"4603_CR6","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/s1470-2045(16)30126-7","volume":"17","author":"JS Weber","year":"2016","unstructured":"J.S. Weber, G. Gibney, R.J. Sullivan et al., Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (checkmate 064): An open-label, randomised, phase 2 trial. Lancet Oncol. 17, 943\u2013955 (2016). https:\/\/doi.org\/10.1016\/s1470-2045(16)30126-7","journal-title":"Lancet Oncol."},{"key":"4603_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/s1470-2045(15)70054-9","volume":"16","author":"NA Rizvi","year":"2015","unstructured":"N.A. Rizvi, J. Mazieres, D. Planchard et al., Activity and safety of nivolumab, an anti-pd-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (checkmate 063): A phase 2, single-arm trial. Lancet Oncol. 16, 257\u2013265 (2015). https:\/\/doi.org\/10.1016\/s1470-2045(15)70054-9","journal-title":"Lancet Oncol."},{"key":"4603_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/a-0843-3366","volume":"51","author":"J Filette","year":"2019","unstructured":"J. Filette, C.E. Andreescu, F. Cools et al., A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm. Metab. Res. 51, 145\u2013156 (2019). https:\/\/doi.org\/10.1055\/a-0843-3366","journal-title":"Horm. Metab. Res."},{"key":"4603_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"R. Barroso-Sousa, W.T. Barry, A.C. Garrido-Castro et al., Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens a systematic review and meta-analysis. Jama Oncol. 4, 173\u2013182 (2018). https:\/\/doi.org\/10.1001\/jamaoncol.2017.3064","journal-title":"Jama Oncol."},{"key":"4603_CR10","doi-asserted-by":"publisher","unstructured":"E. Niedzialkowska, L. Steafo, S. Alsabti et al., Pembrolizumab-induced thyroid storm. Proceedings (Baylor University. Medical Center). 38, 199\u2013201 (2025). https:\/\/doi.org\/10.1080\/08998280.2024.2413320","DOI":"10.1080\/08998280.2024.2413320"},{"key":"4603_CR11","doi-asserted-by":"publisher","first-page":"e250696","DOI":"10.1136\/bcr-2022-250696","volume":"15","author":"S Kataoka","year":"2022","unstructured":"S. Kataoka, K. Matsuno, K. Sugano et al., Thyroid storm induced by combined nivolumab and ipilimumab immunotherapy in advanced non-small cell lung cancer. Bmj Case Rep. 15, e250696 (2022). https:\/\/doi.org\/10.1136\/bcr-2022-250696","journal-title":"Bmj Case Rep."},{"key":"4603_CR12","doi-asserted-by":"publisher","first-page":"1190491","DOI":"10.3389\/fimmu.2024.1432813","volume":"13","author":"L Huo","year":"2023","unstructured":"L. Huo, C. Wang, H. Ding et al., Severe thyrotoxicosis induced by tislelizumab: A case report and literature review. Front. Oncol. 13, 1190491 (2023). https:\/\/doi.org\/10.3389\/fimmu.2024.1432813","journal-title":"Front. Oncol."},{"key":"4603_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40425-017-0213-x","volume":"5","author":"U Khan","year":"2017","unstructured":"U. Khan, H. Rizvi, D. Sano et al., Nivolumab induced myxedema crisis. J. Immunother. Cancer. 5, 13 (2017). https:\/\/doi.org\/10.1186\/s40425-017-0213-x","journal-title":"J. Immunother. Cancer"},{"key":"4603_CR14","doi-asserted-by":"publisher","unstructured":"S. Gummalla, M. Manjunath, B. Phillips, Myxedema coma: A life-threatening condition in patients using pembrolizumab. Case Reports in Endocrinology. 2020, 8855943 (2020). https:\/\/doi.org\/10.1155\/2020\/8855943","DOI":"10.1155\/2020\/8855943"},{"key":"4603_CR15","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1210\/clinem\/dgad260","volume":"108","author":"Q Zhang","year":"2023","unstructured":"Q. Zhang, X. Jiao, X. Lai, Clinical characters and influence factors of immune checkpoint inhibitor-related thyroid dysfunction. J. Clin. Endocrinol. Metab. 108, 2916\u20132923 (2023). https:\/\/doi.org\/10.1210\/clinem\/dgad260","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4603_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12020-023-03323-9","volume":"81","author":"L Wu","year":"2023","unstructured":"L. Wu, Y. Xu, X. Wang et al., Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center chinese cohort: A retrospective study. Endocrine. 81, 123\u2013133 (2023). https:\/\/doi.org\/10.1007\/s12020-023-03323-9","journal-title":"Endocrine"},{"key":"4603_CR17","doi-asserted-by":"publisher","unstructured":"Y. Wang, X. Yang, J. Ma et al., Thyroid dysfunction (td) induced by pd-1\/pd-l1 inhibitors in advanced lung cancer. Heliyon. 10 (2024). https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27077","DOI":"10.1016\/j.heliyon.2024.e27077"},{"key":"4603_CR18","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1007\/s40618-023-02096-2","volume":"46","author":"RM Ruggeri","year":"2023","unstructured":"R.M. Ruggeri, C.C. Spagnolo, A. Alibrandi et al., Predictors of thyroid adverse events during cancer immunotherapy: A real-life experience at a single center. J. Endocrinol. Invest. 46, 2399\u20132409 (2023). https:\/\/doi.org\/10.1007\/s40618-023-02096-2","journal-title":"J. Endocrinol. Invest."},{"key":"4603_CR19","doi-asserted-by":"publisher","first-page":"1458488","DOI":"10.3389\/fimmu.2024.1458488","volume":"15","author":"J Liu","year":"2024","unstructured":"J. Liu, M. Chen, S. Li et al., Biomarkers in the early stage of pd-1 inhibitor treatment have shown superior predictive capabilities for immune-related thyroid dysfunction. Front. Immunol. 15, 1458488 (2024). https:\/\/doi.org\/10.3389\/fimmu.2024.1458488","journal-title":"Front. Immunol."},{"key":"4603_CR20","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.eprac.2024.07.006","volume":"30","author":"Q Wang","year":"2024","unstructured":"Q. Wang, T. Wu, R. Zhao et al., Development and validation of a prediction model for thyroid dysfunction in patients during immunotherapy. Endocr. Pract. 30, 943\u2013950 (2024). https:\/\/doi.org\/10.1016\/j.eprac.2024.07.006","journal-title":"Endocr. Pract."},{"key":"4603_CR21","doi-asserted-by":"publisher","first-page":"113949","DOI":"10.1016\/j.ejca.2024.113949","volume":"202","author":"OJ Kennedy","year":"2024","unstructured":"O.J. Kennedy, N. Ali, R. Lee et al., Thyroid dysfunction after immune checkpoint inhibitors in a single-centre uk pan-cancer cohort: A retrospective study. Eur. J. Cancer. 202, 113949 (2024). https:\/\/doi.org\/10.1016\/j.ejca.2024.113949","journal-title":"Eur. J. Cancer"},{"key":"4603_CR22","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.3390\/cancers13215465","volume":"13","author":"W Kim","year":"2021","unstructured":"W. Kim, Y.-A. Cho, D.-C. Kim et al., Factors associated with thyroid-related adverse events in patients receiving pd-1 or pd-l1 inhibitors using machine learning models. Cancers. 13, 5465 (2021). https:\/\/doi.org\/10.3390\/cancers13215465","journal-title":"Cancers"},{"key":"4603_CR23","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1111\/imj.16194","volume":"53","author":"JM Inglis","year":"2023","unstructured":"J.M. Inglis, S. Bacchi, A. Troelnikov et al., Machine learning models automate classification of penicillin adverse drug reaction labels. Intern. Med. J. 53, 1485\u20131488 (2023). https:\/\/doi.org\/10.1111\/imj.16194","journal-title":"Intern. Med. J."},{"key":"4603_CR24","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s12877-024-05050-w","volume":"24","author":"A Dai","year":"2024","unstructured":"A. Dai, H. Liu, P. Shen et al., Incorporating preoperative frailty to assist in early prediction of postoperative pneumonia in elderly patients with hip fractures: An externally validated online interpretable machine learning model. BMC Geriatr. 24, 472 (2024). https:\/\/doi.org\/10.1186\/s12877-024-05050-w","journal-title":"BMC Geriatr."},{"key":"4603_CR25","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.cell.2018.05.056","volume":"173","author":"MK Yu","year":"2018","unstructured":"M.K. Yu, J. Ma, J. Fisher et al., Visible machine learning for biomedicine. Cell. 173, 1562\u20131565 (2018). https:\/\/doi.org\/10.1016\/j.cell.2018.05.056","journal-title":"Cell"},{"key":"4603_CR26","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1109\/tnnls.2020.3027314","volume":"32","author":"E Tjoa","year":"2021","unstructured":"E. Tjoa, C. Guan, A survey on explainable artificial intelligence (xai): Toward medical xai. Ieee Trans. Neural Networks Learn. Syst. 32, 4793\u20134813 (2021). https:\/\/doi.org\/10.1109\/tnnls.2020.3027314","journal-title":"Ieee Trans. Neural Networks Learn. Syst."},{"key":"4603_CR27","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"D.S. Ross, H.B. Burch, D.S. Cooper et al., 2016 american thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 26, 1343\u20131421 (2016). https:\/\/doi.org\/10.1089\/thy.2016.0229","journal-title":"Thyroid"},{"key":"4603_CR28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2307\/2685209","volume":"46","author":"N Regression","year":"1992","unstructured":"N. Regression, An introduction to kernel and nearest-neighbor. Am. Stat. 46, 175\u2013185 (1992). https:\/\/doi.org\/10.2307\/2685209","journal-title":"Am. Stat."},{"key":"4603_CR29","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3844\/jcssp.2006.735.739","volume":"2","author":"LA Shalabi","year":"2006","unstructured":"L.A. Shalabi, Z. Shaaban, B. Kasasbeh, Data mining: A preprocessing engine. J. Comput. Sci. 2, 735\u2013739 (2006). https:\/\/doi.org\/10.3844\/jcssp.2006.735.739","journal-title":"J. Comput. Sci."},{"key":"4603_CR30","doi-asserted-by":"publisher","first-page":"13036","DOI":"10.1038\/s41598-019-49539-6","volume":"9","author":"S. Okada","year":"2019","unstructured":"S.Okada, M. Ohzeki, S. Taguchi, Efficient partition of integer optimization problems with one-hot encoding. Sci. Rep. 9, 13036 (2019). https:\/\/doi.org\/10.1038\/s41598-019-49539-6","journal-title":"Sci. Rep."},{"key":"4603_CR31","doi-asserted-by":"publisher","unstructured":"R. Tibshirani, Regression shrinkage and selection via the lasso: A retrospective. Journal of the Royal Statistical Society Series B-Statistical Methodology. 73, 273\u2013282 (2011). https:\/\/doi.org\/10.1111\/j.1467-9868.2011.00771.x","DOI":"10.1111\/j.1467-9868.2011.00771.x"},{"key":"4603_CR32","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"E.R. DeLong, D.M. DeLong, D.L. Clarke-Pearson, Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics. 44, 837\u2013845 (1988). https:\/\/doi.org\/10.2307\/2531595","journal-title":"Biometrics"},{"key":"4603_CR33","doi-asserted-by":"publisher","first-page":"1187725","DOI":"10.3389\/fendo.2023.1187725","volume":"14","author":"S Csiha","year":"2023","unstructured":"S. Csiha, I. Molnar, S. Halmi et al., Advanced glycation end products and their soluble receptor (srage) in patients with hashimoto\u2019s thyroiditis on levothyroxine substitution. Front. Endocrinol. 14, 1187725 (2023). https:\/\/doi.org\/10.3389\/fendo.2023.1187725","journal-title":"Front. Endocrinol."},{"key":"4603_CR34","doi-asserted-by":"publisher","first-page":"1581057","DOI":"10.3389\/fimmu.2025.1581057","volume":"16","author":"P Zhao","year":"2025","unstructured":"P. Zhao, J. Li, L. Yu et al., Clinical manifestations and risk factors of immune-related thyroid adverse events in patients treated with pd-1 inhibitors: A case-control study. Front. Immunol. 16, 1581057 (2025). https:\/\/doi.org\/10.3389\/fimmu.2025.1581057","journal-title":"Front. Immunol."},{"key":"4603_CR35","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/cen.14349","volume":"94","author":"I Yamauchi","year":"2021","unstructured":"I. Yamauchi, D. Taura, T. Hakata et al., Clinical features and thyroid dysfunction in adverse events involving the pituitary gland during pd-1 blockade therapy. Clin. Endocrinol. (Oxf). 94, 258\u2013268 (2021). https:\/\/doi.org\/10.1111\/cen.14349","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"4603_CR36","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/cei\/uxad105","volume":"214","author":"J Li","year":"2023","unstructured":"J. Li, W. Shi, J. Xiong et al., Toxicity spectrum and risk factors for chemo-immunotherapy in locally advanced or metastatic lung cancer. Clin. Exp. Immunol. 214, 162\u2013169 (2023). https:\/\/doi.org\/10.1093\/cei\/uxad105","journal-title":"Clin. Exp. Immunol."},{"key":"4603_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.lungcan.2021.08.009","volume":"161","author":"N Zhou","year":"2021","unstructured":"N. Zhou, M.A. Velez, B. Bachrach et al., Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in nsclc. Lung Cancer. 161, 34\u201341 (2021). https:\/\/doi.org\/10.1016\/j.lungcan.2021.08.009","journal-title":"Lung Cancer"},{"key":"4603_CR38","doi-asserted-by":"publisher","first-page":"649863","DOI":"10.3389\/fendo.2021.649863","volume":"12","author":"L Zhan","year":"2021","unstructured":"L. Zhan, H.-. Feng, H.-. Liu et al., Immune checkpoint inhibitors-related thyroid dysfunction: Epidemiology, clinical presentation, possible pathogenesis, and management. Front. Endocrinol. 12, 649863 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.649863","journal-title":"Front. Endocrinol."},{"key":"4603_CR39","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","volume":"47","author":"MA Coelho","year":"2017","unstructured":"M.A. Coelho, S. de Carn\u00e9 Tr\u00e9cesson, S. Rana et al., Oncogenic ras signaling promotes tumor immunoresistance by stabilizing pd-l1 mrna. Immunity. 47, 1083\u20131099 (2017). https:\/\/doi.org\/10.1016\/j.immuni.2017.11.016","journal-title":"Immunity"},{"key":"4603_CR40","doi-asserted-by":"publisher","first-page":"101660","DOI":"10.1016\/j.beem.2022.101660","volume":"36","author":"S Iwama","year":"2022","unstructured":"S. Iwama, T. Kobayashi, Y. Yasuda et al., Immune checkpoint inhibitor-related thyroid dysfunction. Best Pract. Res. Clin. Endocrinol. Metab. 36, 101660\u2013101660 (2022). https:\/\/doi.org\/10.1016\/j.beem.2022.101660","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"4603_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fendo.2025.1584675","volume":"16","author":"XQ Mao","year":"2025","unstructured":"X.Q. Mao, C.M. Mao, J.M. Liu et al., Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms. Front. Endocrinol. 16, 11 (2025). https:\/\/doi.org\/10.3389\/fendo.2025.1584675","journal-title":"Front. Endocrinol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04603-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04603-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04603-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:53:51Z","timestamp":1775105631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04603-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4603"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04603-w","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"131"}}